Restricted accessBrief reportFirst published online 2023-05-16
Serum Cathepsin S Levels Do Not Show Alterations in Different Clinical,Neuropathological,or Genetic Subtypes of Frontotemporal Dementia Patients nor in Comparison to Healthy Control Individuals
Frontotemporal dementia (FTD) can manifest as diverse clinical phenotypes and is frequently caused by mutations in different genes, complicating differential diagnosis. This underlines the urgent need for valid biomarkers. Altered lysosomal and immune functions proposedly contribute to FTD pathogenesis. Cathepsins, including cathepsin S, are enzymes preferentially expressed in brain in microglia, which influence lysosomal and immune function. Here, we examined whether alterations in serum cathepsin S levels associate with specific clinical, genetic, or neuropathological FTD subgroups, but no such alterations were observed. However, further research on other lysosomal proteins may reveal new biologically relevant biomarkers in FTD.
SiebenA, Van LangenhoveT, EngelborghsS, MartinJJ, BoonP, CrasP, De DeynPP, SantensP, Van BroeckhovenC, CrutsM (2012) The genetics and neuropathology of frontotemporal lobar degeneration, Acta Neuropathol124, 353–372.
de DuveC (2005) The lysosome turns fifty, Nat Cell Biol7, 847–849.
5.
DengZ, SheehanP, ChenS, YueZ (2017) Is amyotrophic lateral sclerosis/frontotemporal dementia an autophagy disease? Mol Neurodegener12, 1–11.
6.
RootJ, MerinoP, NuckolsA, JohnsonM, KukarT (2021) Lysosome dysfunction as a cause of neurodegenerative diseases: Lessons from frontotemporal dementia and amyotrophic lateral sclerosis, Neurobiol Dis154, 105360.
7.
CastertonRL, HuntRJ, FantoM (2020) Pathomechanism heterogeneity in the amyotrophic lateral sclerosis and frontotemporal dementia disease spectrum: Providing focus through the lens of autophagy, J Mol Biol432, 2692–2713.
8.
YadatiT, HoubenT, BitorinaA, Shiri-SverdlovR (2020) The ins and outs of cathepsins: Physiological function and role in disease management, Cells9, 1679.
9.
RossiA, DeverauxQ, TurkB, SaliA (2004) Comprehensive search for cysteine cathepsins in the human genome, Biol Chem385, 363–372.
10.
HookV, YoonM, MosierC, ItoG, PodvinS, HeadBP, RissmanR, O’DonoghueAJ, HookG (2020) Cathepsin B in neurodegeneration of Alzheimer’s disease, traumatic brain injury, and related brain disorders, Biochim Biophys Acta Proteins Proteom1868, 140428.
ChitramuthuBP, BennettHPJ, BatemanA (2017) Progranulin:Anewavenue towards the understanding and treatment of neurodegenerative disease.Brain140, 3081–3104.
PišlarA, BolčinaL, KosJ (2021) New insights into the role of cysteine cathepsins in neuroinflammation, Biomolecules11, 1796.
24.
LeeCW, StankowskiJN, ChewJ, CookCN, LamYW, AlmeidaS, CarlomagnoY, LauKF, PrudencioM, GaoFB, BogyoM, DicksonDW, PetrucelliL (2017) The lysosomal protein cathepsin L is a progranulin protease, Mol Neurodegener12, 55.
25.
BelliniS, SaracenoC, BenussiL, GevitiA, LongobardiA, NicsanuR, CiminiS, RicciM, CanafogliaL, CoppolaC, PuotiG, BinettiG, RossiG, GhidoniR (2022) Plasma small extracellular vesicle cathepsin D dysregulation in GRN/C9orf72 and sporadic frontotemporal lobar degeneration, Int J Mol Sci23, 10693.
26.
SteublD, KumarS V., TatoM, MulaySR, LarssonA, LindL, RisérusU, RendersL, HeemannU, CarlssonAC, ÄrnlövJ, AndersHJ (2017) Circulating cathepsin-S levels correlate with GFRdecline and sTNFR1 and sTNFR2 levels in mice and humans, SciRep7, 43538.
27.
SonkarSK, SinghPK, ChandraS, SonkarGK, BhosaleV, SharmaS (2022) Cathepsin S as an early biomarker for cardiovascular disease in chronic kidney disease patients, Braz J Nephrol44, 329–335.
